A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models

被引：0
|
作者：
Okpalanwaka, Izuchukwu F.
Daugherity, Elizabeth A.
McCormick, Amanda L.
Anderson, Trevor S.
Smith, Savanna L.
Lawrence, Caryn
Lowe, Devin B.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2024年 / 12卷 / 10期
关键词：
D O I：
10.1158/2326-6074.TUMIMM24-B010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B010
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A LAG-3/PD-L1 bispecific antibody inhibits tumour growth in two syngeneic colon carcinoma models
    Everett, Katy
    Kraman, Matthew
    Kmiecik, Katarzyna
    Allen, Natalie
    Faroudi, Mustapha
    Zimarino, Carlo
    Wydro, Mateusz
    Doody, Jacqueline
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [42] In vitro-irradiated cancer vaccine enhances anti-tumor efficacy of radiotherapy and PD-L1 blockade in a syngeneic murine breast cancer model
    Kim, Yoomin
    Jeon, Seung Hyuck
    Kim, Seongmin
    Kang, Mi Hyun
    Han, Min Guk
    Lee, Se Yup
    Kim, In Ah
    RADIOTHERAPY AND ONCOLOGY, 2024, 200
  • [43] Microenvironment-responsive anti-PD-L1 x CD3 bispecific T-cell engager for solid tumor immunotherapy
    Liu, Dingkang
    Bao, Lichen
    Zhu, Haichao
    Yue, Yali
    Tian, Jing
    Gao, Xiangdong
    Yin, Jun
    JOURNAL OF CONTROLLED RELEASE, 2023, 354 : 606 - 614
  • [44] Pre-clinical efficacy in multiple syngeneic models with oral immune checkpoint antagonists targeting PD-L1 and TIM-3
    Sasikumar, P.
    Sudarshan, N.
    Ramachandra, R.
    Gowda, N.
    Samiulla, D.
    Bilugudi, P.
    Adurthi, S.
    Mani, J.
    Nair, R.
    Gowda, N.
    Ramachandra, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S98 - S98
  • [45] PD-1/PD-L1 expression and regorafenib clinical efficacy on refractory pancreatic cancer patient.
    Varchetta, Veronica
    Montagnese, Fabrizio
    Sibio, Simone
    Sica, Giuseppe
    Muscaritoli, Maurizio
    Soda, Giuseppe
    Giordano, Gianfranco
    Brandi, Rita
    Tarsi, Silvia
    Mancuso, Giuseppina
    Mancuso, Andrea Petricca
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity.
    Hsu, Michelle A.
    Liu, Xin
    Barham, Whitney
    Hirdler, Jacob
    Mao, Zhiming
    Lucien, Fabrice
    Dong, Haidong
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [47] PD-L1 Checkpoint Blockade Using a Single-Chain Variable Fragment Targeting PD-L1 Delivered by Retroviral Replicating Vector Enhances Anti-Tumor Effect in Cancer Models
    Lin, Amy H.
    Yagiz, Kader
    Hofacre, Andrew
    Munday, Anthony W.
    Espinoza, Fernando Lopez
    Mendoza, Daniel
    Burrascano, Cynthia
    Gruber, Harry E.
    Mitchell, Leah A.
    Jolly, Douglas J.
    MOLECULAR THERAPY, 2018, 26 (05) : 54 - 54
  • [48] A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity
    Luan, Yan
    Chai, Dafei
    Peng, Jianjian
    Ma, Shuli
    Wang, Min
    Ma, Hui
    Li, Xiang
    Fu, Shilong
    Pan, Xiaolong
    Wang, Xiaoxiao
    Qin, Songbing
    Xu, Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 31 : 248 - 256
  • [49] TLS11a Aptamer/CD3 Antibody Anti-Tumor System for Liver Cancer
    Hu, Zixi
    He, Jian
    Gong, Wenlin
    Zhou, Nuo
    Zhou, Sufang
    Lai, Zongqiang
    Zheng, Rong
    Wang, Yiwei
    Yang, Xiaomei
    Yang, Wei
    Zhong, Liping
    Lu, Xiaoling
    Zhao, Yongxiang
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2018, 14 (09) : 1645 - 1653
  • [50] Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and exerts synergistic anti-tumor activity with an anti-PD-1 antibody in colon cancer
    Fu, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1843 - 1843
12345